England's NHS Proposes Phased Rollout of Eli Lilly's Mounjaro, Considers Digital Services to Boost Access
England's NHS Proposes Phased Rollout of Eli Lilly's Mounjaro, Considers Digital Services to Boost Access
NHS England has proposed a phased rollout of tirzepatide, a promising weight-loss drug, to benefit patients most likely to achieve significant clinical outcomes.
NHS England已提議分階段推出曲塞帕肽，這是一種前景看好的減肥藥物，以使最有可能取得重大臨床療效的患者受益。
Tirzepatide, branded as Mounjaro and produced by Eli Lilly And Co (NYSE:LLY), has shown remarkable results in clinical trials. It offers greater weight loss than existing therapies like Novo Nordisk A/S' (NYSE:NVO) and Ozempic (semaglutide).
名爲Mounjaro的Tirzepatide由禮來公司（紐約證券交易所代碼：LLY）生產，在臨床試驗中顯示出顯著成果。與諾和諾德A/S（紐約證券交易所代碼：NVO）和Ozempic（索瑪魯肽）等現有療法相比，它具有更大的減肥效果。
In the SURMOUNT-4 trial, patients lost an average of 20.9% of their body weight in 36 weeks.
在SurMount-4試驗中，患者在36周內平均減輕了20.9％的體重。
Also Read: Popular Weight Loss Drugs Like Ozempic Show Gap Between Clinical Trial Promises And Real-World Use, Study Reveals.
另請閱讀：研究顯示，像Ozempic這樣的流行減肥藥物在臨床試驗承諾與實際使用之間存在差距。
The plan, currently under consultation, aims to test various medication delivery models before expanding its availability.
該計劃目前正在磋商中，旨在在擴大其可用性之前測試各種藥物交付模式。
Under draft guidance from an independent committee at the National Institute for Health and Care Excellence (NICE), tirzepatide has been recommended for patients living with obesity, with a maximum list price of 122 pounds ($159.6) per month for the highest dose.
根據美國國家健康與護理卓越研究所（NICE）獨立委員會的指導方針草案，建議肥胖患者使用替塞帕肽，最高劑量的最高標價爲每月122磅（合159.6美元）。
The phased launch will integrate tirzepatide into community-based services and digital health platforms to expand accessibility.
分階段啓動將把tirzepatide整合到社區服務和數字健康平台中，以擴大可及性。
The rollout will target up to 240,000 people in the first three years and evaluate cost-effective delivery models, including virtual clinics.
此次推出將在前三年針對多達24萬人，並評估包括虛擬診所在內的具有成本效益的交付模式。
Eligible patients will be categorized based on their BMI and related health conditions. Initially, those with a BMI above 40 and three or more weight-related conditions, such as hypertension and cardiovascular disease, will qualify.
符合條件的患者將根據其體重指數和相關健康狀況進行分類。最初，體重指數高於40且有三種或更多與體重相關的疾病（例如高血壓和心血管疾病）的人將符合資格。
Obesity is a significant challenge for the NHS, with annual treatment costs reaching 11.4 billion pounds ($14.91 billion).
肥胖是國民保健服務面臨的重大挑戰，每年的治療費用達到114英鎊（合149.1億美元）。
According to the Health Survey for England 2022, about 64% of adults in the country are overweight or obese.
根據2022年英格蘭健康調查，該國約有64％的成年人超重或肥胖。
The consultation period for the rollout plan is currently open, with final guidance from NICE expected later this year.
該推出計劃的磋商期目前已開始，預計NICE將在今年晚些時候提供最終指導。
Earlier this week, Eli Lilly announced a $4.5 billion investment to create the Lilly Medicine Foundry, a new center for advanced manufacturing and drug development, as the company inches closer to becoming the first pharma company in the $1 trillion club.
本週早些時候，禮來公司宣佈投資45億美元創建禮來藥品鑄造廠，這是一個新的先進製造和藥物開發中心，因爲該公司即將成爲這個1萬億美元俱樂部中的第一家制藥公司。
Price Action: LLY stock is down 0.23% at $883.56 at the last check Friday.
價格走勢：在週五的最後一次支票中，LLY股價下跌0.23％，至883.56美元。
- Novo Nordisk/AstraZeneca's Manufacturing Partner Thermo Fisher Questioned Over Manufacturing Lapses.
- Novo Nordisk/阿斯利康的製造合作伙伴Thermo Fisher因製造失誤受到質疑。
Photo via Company
照片來自公司